Nimustine treatment results for cats with lymphoma

Abstract

Abstract Background Nimustine, similar to lomustine, is an alkylating agent from the nitrosourea family. There have been some reports regarding lomustine treatment for tumour‐bearing cats. However, information regarding nimustine treatment for tumour‐bearing cats is limited. Objectives To retrospectively evaluate adverse events and clinical outcomes in tumour‐bearing cats receiving nimustine. Methods Information regarding diagnosis, treatment condition, adverse events, and clinical outcomes was collected in tumour‐bearing cats receiving nimustine through reviews of medical records. Results Nine cats with lymphoma were treated with nimustine in the primary therapy (n = 2) and in the rescue therapy (n = 7). Median starting dose of nimustine was 25 mg/m2 (range: 20–30 mg/m2) with dosing interval of three weeks and 1–11 administrations. Adverse events were mild gastrointestinal toxicity (grade 1) including diarrhoea (n = 2) and vomiting (n = 2) and mild myelosuppression (grade 1 or 2) including thrombocytopenia (n = 3) and neutropenia (n = 1). No severe adverse events were observed. Progression‐free survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 274–688 days (median: 481 days) and 9–671 days (median: 102 days), respectively. Overall survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 275–745 days (median: 510 days) and 14–671 days (median: 109 days), respectively. Conclusions Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma. These findings suggest that nimustine might be an alternative to lomustine in the treatment of feline lymphoma.